机器人辅助腹腔镜与传统腹腔镜在临床I期上皮性卵巢癌中的生存结局
基于美国国家癌症数据库2010至2014年1901例临床I期上皮性卵巢癌微创手术患者,比较机器人辅助腹腔镜与传统腹腔镜的长期死亡率。机器人组中转开腹率7.2%低于传统组17.9%(P<.001;调整OR 0.49,95%CI 0.33-0.73),1、3、5年调整死亡风险比分别为0.97(95%CI 0.43-2.18)、0.68(95%CI 0.43-1.08)、0.78(95%CI 0.53-1.16),总体死亡率无显著差异。
要点
- 机器人辅助腹腔镜中转开腹率7.2%,低于传统腹腔镜的17.9%(P<.001)。
- 1、3、5年调整死亡风险比分别为0.97、0.68、0.78,95%CI均跨1。
- 机器人辅助腹腔镜与传统腹腔镜总体死亡率相当。
核心结论
- 在临床I期上皮性卵巢癌中,机器人辅助腹腔镜与传统腹腔镜的总体死亡率相当。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入2010至2014年接受微创手术(机器人辅助腹腔镜或传统腹腔镜)的临床I期上皮性卵巢癌患者共1901例。
主要发现
- 机器人辅助腹腔镜中转开腹率为7.2%,低于传统腹腔镜的17.9%(P<.001;调整OR 0.49,95%CI 0.33-0.73)。
- 机器人辅助腹腔镜组与传统腹腔镜组1年调整死亡风险比为0.97(95%CI 0.43-2.18),无显著差异。
- 3年调整死亡风险比为0.68(95%CI 0.43-1.08),无显著差异。
- 5年调整死亡风险比为0.78(95%CI 0.53-1.16),无显著差异。
关键数值与推荐
- 中转开腹率:机器人辅助腹腔镜7.2% vs 传统腹腔镜17.9%(P<.001;调整OR 0.49,95%CI 0.33-0.73)。
- 1年调整死亡风险比:0.97(95%CI 0.43-2.18)。
- 3年调整死亡风险比:0.68(95%CI 0.43-1.08)。
- 5年调整死亡风险比:0.78(95%CI 0.53-1.16)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The US Food and Drug Administration recently called for studies addressing long-term survival after robotic-assisted laparoscopy in oncologic settings. Long-term clinical outcomes of robotic-assisted laparoscopy among ovarian cancer patients are understudied. OBJECTIVE(S): To investigate the long-term mortality of robotic-assisted laparoscopy compared to traditional laparoscopy for clinical stage I epithelial ovarian cancer. MATERIALS AND METHODS: Using data from the National Cancer Database, we identified a total of 1901 patients who received minimally invasive surgery (ie, robotic-assisted laparoscopy or traditional laparoscopy) for clinical stage I epithelial ovarian cancer between 2010 and 2014. Multivariable logistic or linear regression analyses were conducted to evaluate the short-term outcomes, including conversion-to-open surgery, number of lymph nodes examined, length of hospitalization, unplanned 30-day readmission, and 30- and 90-day mortality. Multivariable Cox proportional hazards models were used to derive adjusted hazard ratios and 95% confidence intervals for 1-, 3-, and 5-year total mortality associated with surgical approaches. Covariates adjusted for included age, tumor size and upstaging, number of lymph nodes evaluated, time from diagnosis to surgery, length of hospitalization, histologic subtype, insurance status, region, distance to care, surgical procedure type, and hospital experience with these procedures. RESULTS: Compared to traditional laparoscopy, robotic-assisted laparoscopy was less likely to result in conversion-to-open surgery (conversion rate: 7.2% versus 17.9%, P < .001; adjusted odds ratio, 0.49; 95% confidence interval, 0.33-0.73). In multivariable analyses, there were no significant differences in survival between robotic-assisted laparoscopy- and traditional laparoscopy-treated patients. Compared with traditional laparoscopy, the adjusted hazard ratios for 1-, 3-, and 5-year mortality were 0.97 (95% confidence interval, 0.43-2.18), 0.68 (95% confidence interval, 0.43-1.08), and 0.78 (95% confidence interval, 0.53-1.16), respectively. CONCLUSION(S): Robotic-assisted laparoscopy had comparable overall mortality in comparison to traditional laparoscopy when treating clinical stage I epithelial ovarian cancer.
引用
- Facer B, Wang F, Grijalva CG, et al. Survival outcomes for robotic-assisted laparoscopy versus traditional laparoscopy in clinical stage I epithelial ovarian cancer. Am J Obstet Gynecol. 2019. PMID: 31715149. doi:10.1016/j.ajog.2019.10.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。